Subcutaneous efalizumab is not effective in the treatment of alopecia areata.

Published

Journal Article

BACKGROUND: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis. OBJECTIVE: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA. METHODS: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods-a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up. RESULTS: There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated. LIMITATIONS: Numbers were too small for certain analyses. CONCLUSION: A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.

Full Text

Duke Authors

Cited Authors

  • Price, VH; Hordinsky, MK; Olsen, EA; Roberts, JL; Siegfried, EC; Rafal, ES; Korman, NJ; Altrabulsi, B; Leung, HM; Garovoy, MR; Caro, I; Whiting, DA

Published Date

  • March 2008

Published In

Volume / Issue

  • 58 / 3

Start / End Page

  • 395 - 402

PubMed ID

  • 18280336

Pubmed Central ID

  • 18280336

Electronic International Standard Serial Number (EISSN)

  • 1097-6787

Digital Object Identifier (DOI)

  • 10.1016/j.jaad.2007.10.645

Language

  • eng

Conference Location

  • United States